Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06255379
Other study ID # ZF-2023-387-01
Secondary ID HMPL-013-SC-CRC1
Status Not yet recruiting
Phase Phase 2
First received
Last updated
Start date May 6, 2024
Est. completion date March 21, 2027

Study information

Verified date April 2024
Source Guangzhou University of Traditional Chinese Medicine
Contact Yang xiaobing, PhD
Phone +86 135-8030-9705
Email yangxiaobing2002@126.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is an Open, Single-arm, Multicenter, Prospective Phase II Study of Fuquinitinib Combined With Tegafur Gimeracil Oteracil in the Third-line Treatment of Patients With Advanced Metastatic CRC


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 52
Est. completion date March 21, 2027
Est. primary completion date March 21, 2027
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: 1. = 18 and = 75 years of age; 2. Have fully understood and voluntarily sign the ICF for this study (the icf must be signed before any trial-specific procedures are performed);Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedure; 3. Histologically and/or cytologically documented metastatic colorectal adenocarcinoma; 4. Refractory to at least second line standard treatment containing fluorouracil, oxaliplatin and irinotecan; 5. At least one measurable lesion (larger than 10 mm in diameter by spiral CT scan or 20mm by conventional CT scan); 6. ECOG performance status of 0-1; 7. Life expectancy = 12 weeks; 8. No previous treatment with vascular endothelial growth factor receptor (VEGFR) inhibitor (TKI); 9. Adequate hepatic, renal, heart, and hematologic functions; 10. Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedure. Exclusion Criteria: 1. Pregnant or lactating women; 2. Any factors that influence the usage of oral administration or any disease or condition that affects drug absorption; 3. Previous treatment with Tegafur Gimeracil Oteracil ; 4. Participated in clinical trials of other drugs within four weeks before enrollment; 5. Received other systemic anti-tumor therapy within 4 weeks before enrollment, including chemotherapy, signal transduction inhibitors, hormone therapy and immunotherapy; 6. International normalized ratio (INR) > 1.5 or partially activated prothrombin time (APTT) > 1.5 × ULN; 7. Clinically significant electrolyte abnormalities; 8. Subjected with hypertension that cannot be controlled by drugs, which is specified as: systolic blood pressure = 140 mmHg and / or diastolic blood pressure = 90 mmHg; 9. Unrelieved toxic reactions higher than CTCAE V5.0 grade 1 caused by any previous anti-cancer treatment; 10. Incomplete healing of skin wound, surgical site, traumatic site, severe mucosal ulcer or fracture; 11. Conditions that may cause gastrointestinal bleeding and perforation determined by the researcher; 12. History of arterial thrombosis or deep venous thrombosis within 6 months before enrollment; 13. Stroke and / or transient cerebral ischemia occurred within 12 months before enrollment; 14. Cardiovascular diseases with significant clinical significance; 15. LVEF<50%; 16. Congestive heart failure New York Heart Association (NYHA) grade > 2; 17. Evidence of CNS metastasis; 18. Previous treatment with VEGFR inhibition; 19. Ventricular arrhythmias requiring drug treatment; 20. Proteinuria = 2+ (1.0g/24hr); 21. Coagulation dysfunction, hemorrhagic tendency or receiving anticoagulant therapy; 22. Other malignant tumors in the past 5 years, except skin basal cell or squamous cell carcinoma after radical surgery, or cervical carcinoma in situ; 23. Active infection that is not controlled clinically, such as acute pneumonia, active hepatitis B or hepatitis C; 24. By judgment of the investigator, there are concomitant diseases that seriously endanger the safety of the patient or affect the completion of the study.

Study Design


Intervention

Drug:
Fuquinitinib+Tegafur Gimeracil Oteracil
Fuquinitinib:5 mg once daily, 2 weeks on/1 week off,q3w; Tegafur Gimeracil Oteracil:BSA(body surface area)< 1.2m2,40mg/m2,p.o,bid,2 weeks on/1 week off,q3w; 1.2m2 < BSA (body surface area)< 1.5m2,50mg/m2,p.o,bid,2 weeks on/1 week off,q3w;BSA(body surface area) >1.5m2,60mg/m2,p.o,bid,2 weeks on/1 week off,q3w;

Locations

Country Name City State
China Guangdong Provincial Hospital of Traditional Chinese Medicine Guangzhou Guangdong

Sponsors (1)

Lead Sponsor Collaborator
Guangzhou University of Traditional Chinese Medicine

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Progression Free Survival (PFS) PFS is defined as the time from enrollment to the first documented disease progression or death due to any cause, whichever occurs first. Responses are according to the Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) as assessed by investigator from randomization up to progressive disease or EOT due to any cause, up to 2 years
Secondary Objective response rate(ORR) Defined as percentage of participants achieving assessed complete response (CR) and partial response (PR) by the investigator according to the RECIST 1.1. from randomization up to progressive disease or EOT due to any cause, up to 2 years
Secondary Disease control rate(DCR) DCR was defined as the percentage of participants who have a confirmed complete response(CR) or partial response(PR) or stable disease(SD) per RECIST 1.1 as assessed by investigator from randomization up to progressive disease or EOT due to any cause, up to 2 years
Secondary Overall survival (OS) OS is the time from enrollment to death due to any cause. from randomization up to progressive disease or EOT due to any cause, up to 3 years
Secondary adverse events (AE) overall incidence of adverse events (AE); incidence of grade 3 or higher AE; incidence of severe adverse events (SAE); incidence of AEs leading to discontinuation of drug use; incidence of AEs leading to suspension of drug use. from day 1 of first dosing to 30days after permanent discontinuation of fruquintinib
See also
  Status Clinical Trial Phase
Recruiting NCT06380101 - Evaluating a Nonessential Amino Acid Restriction (NEAAR) Medical Food With Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer (LARC) N/A
Active, not recruiting NCT05551052 - CRC Detection Reliable Assessment With Blood
Recruiting NCT04323722 - Impact of Bladder Depletion on Mesorectal Movements During Radiotherapy in Rectal Cancer N/A
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT04088955 - A Digimed Oncology PharmacoTherapy Registry
Active, not recruiting NCT01347697 - Collagen Implant (Biological Mesh) Versus GM Flap for Reconstruction of Pelvic Floor After ELAPE in Rectal Cancer N/A
Recruiting NCT04495088 - Preoperative FOLFOX Versus Postoperative Risk-adapted Chemotherapy in Patients With Locally Advanced Rectal Cancer Phase 3
Withdrawn NCT03007771 - Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) Used for Mild Hyperthermia Phase 1
Terminated NCT01347645 - Irinotecan Plus E7820 Versus FOLFIRI in Second-Line Therapy in Patients With Locally Advanced or Metastatic Colon or Rectal Cancer Phase 1/Phase 2
Not yet recruiting NCT03520088 - PROSPECTIVE CONTROLLED AND RANDOMIZED STUDY OF THE GENITOURINARY FUNCTION AFTER RECTAL CANCER SURGERY IN RELATION TO THE DISSECTION OF THE INFERIOR MESENTERIC VESSELS N/A
Recruiting NCT05556473 - F-Tryptophan PET/CT in Human Cancers Phase 1
Recruiting NCT04749381 - The Role of TCM on ERAS of Rectal Cancer Patients Phase 2
Enrolling by invitation NCT05028192 - Mitochondria Preservation by Exercise Training: a Targeted Therapy for Cancer and Chemotherapy-induced Cachexia
Recruiting NCT03283540 - Transanal Total Mesorectal Excision for Rectal Cancer on Anal Physiology + Fecal Incontinence
Completed NCT04534309 - Behavioral Weight Loss Program for Cancer Survivors in Maryland N/A
Recruiting NCT05914766 - An Informational and Supportive Care Intervention for Patients With Locally Advanced Rectal Cancer N/A
Recruiting NCT04852653 - A Prospective Feasibility Study Evaluating Extracellular Vesicles Obtained by Liquid Biopsy for Neoadjuvant Treatment Response Assessment in Rectal Cancer
Recruiting NCT03190941 - Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients Phase 1/Phase 2
Terminated NCT02933944 - Exploratory Study of TG02-treatment as Monotherapy or in Combination With Pembrolizumab to Assess Safety and Immune Activation in Patients With Locally Advanced Primary and Recurrent Oncogenic RAS Exon 2 Mutant Colorectal Cancer Phase 1
Completed NCT02810652 - Perioperative Geriatrics Intervention for Older Cancer Patients Undergoing Surgical Resection N/A